Solveig Billing Clason

Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long‐term secondary prevention of venous thromboembolism

S. Schulman, P. Wessman, H. Eriksson, 2006, British journal of haematology.

Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

S. Schulman, H. Eriksson, K. Wåhlander, 2003, The New England journal of medicine.

Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran

S. Schulman, H. Eriksson, K. Wåhlander, 2005, Thrombosis and Haemostasis.

Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

S. Schulman, H. Eriksson, K. Wåhlander, 2003, The New England journal of medicine.